RxSight, Inc. (RXST)
NASDAQ: RXST · Real-Time Price · USD
8.11
-0.10 (-1.22%)
At close: Oct 9, 2025, 4:00 PM EDT
8.12
+0.01 (0.12%)
After-hours: Oct 9, 2025, 7:28 PM EDT
RxSight Revenue
RxSight had revenue of $33.64M in the quarter ending June 30, 2025, a decrease of -3.58%. This brings the company's revenue in the last twelve months to $147.06M, up 27.68% year-over-year. In the year 2024, RxSight had annual revenue of $139.93M with 57.09% growth.
Revenue (ttm)
$147.06M
Revenue Growth
+27.68%
P/S Ratio
2.23
Revenue / Employee
$295,299
Employees
498
Market Cap
331.83M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 139.93M | 50.85M | 57.09% |
Dec 31, 2023 | 89.08M | 40.07M | 81.77% |
Dec 31, 2022 | 49.01M | 26.41M | 116.90% |
Dec 31, 2021 | 22.59M | 7.92M | 53.92% |
Dec 31, 2020 | 14.68M | 12.44M | 554.98% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2005 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2004 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2003 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
RXST News
- 17 days ago - The Bottom Fishing Club - RxSight: A Ski-Jump Reversal Pattern? - Seeking Alpha
- 17 days ago - RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXST - PRNewsWire
- 18 days ago - SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight - GlobeNewsWire
- 23 days ago - DEADLINE NEXT WEEK: Berger Montague Advises RxSight, Inc. (NASDAQ: RXST) Investors to Contact the Firm Before September 22, 2025 - GlobeNewsWire
- 25 days ago - RXST STOCK NEWS: RxSight, Inc. Investors Urged to Act by September 22 Court Deadline -- Contact BFA Law if You Suffered Losses - GlobeNewsWire
- 27 days ago - RXST SECURITIES NOTICE: Did RxSight, Inc. Mislead Investors? Contact BFA Law if You Lost Money on Your Investment - GlobeNewsWire
- 4 weeks ago - RxSight, Inc. (RXST) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight - PRNewsWire